Breakthru Medicine focuses on aggressive solid tumors with the highest unmet need—cancers where patients have exhausted existing options. By attacking the specific molecular drivers of each tumor, we design precision therapies for patients whose cancers have become resistant to current treatments.

Breakthru Medicine is a privately held preclinical biotechnology company founded by industry veterans with over a dozen FDA approvals between them— and a majority with breakthrough therapy designations. We're building multiple independent scientific platforms, each designed to crack a different class of previously untreatable cancers. The Breakthru team has spent decades solving medicinal chemistry problems that others walked away from, turning "undruggable" targets into precision medicines.

The Breakthru team is not just good at making drugs. We’re exceptional at knowing which drugs not to make. We've learned that the strongest teams exercise data-driven, brutal honesty about when a compound isn't likely to become a breakthrough medicine—and move on efficiently. This pattern recognition only comes from years of drug development experience—both our successes and our scars.

Though preclinical, we know what winning looks like and what chasing the wrong target costs. For patients told, “There are no more options,” we’re building the next ones.

Breakthru Medicine

Org chart

Teams

Offices